Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors

[1]  Triantafyllos Stylianopoulos,et al.  Combining two strategies to improve perfusion and drug delivery in solid tumors , 2013, Proceedings of the National Academy of Sciences.

[2]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[3]  M. Hidalgo,et al.  Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. , 2013 .

[4]  T. Stylianopoulos.  EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. , 2013, Therapeutic delivery.

[5]  M. Hidalgo,et al.  Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). , 2013 .

[6]  Yun Yen,et al.  First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies , 2013, Investigational New Drugs.

[7]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[8]  W. Saltzman,et al.  Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. , 2012, Biomaterials.

[9]  Dai Fukumura,et al.  Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical Model , 2012, Annals of Biomedical Engineering.

[10]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[11]  A. Boddy,et al.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.

[12]  Dai Fukumura,et al.  Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.

[13]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[14]  Dai Fukumura,et al.  A nanoparticle size series for in vivo fluorescence imaging. , 2010, Angewandte Chemie.

[15]  Hemant Sarin,et al.  Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability , 2010, Journal of angiogenesis research.

[16]  Michael Höpfner,et al.  The shunt problem: control of functional shunting in normal and tumour vasculature , 2010, Nature Reviews Cancer.

[17]  Erkki Ruoslahti,et al.  Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.

[18]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[19]  S. Eikenberry.  Theoretical Biology and Medical Modelling Open Access a Tumor Cord Model for Doxorubicin Delivery and Dose Optimization in Solid Tumors , 2022 .

[20]  Michael Höpfner,et al.  Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks , 2009, PLoS Comput. Biol..

[21]  Warren C W Chan,et al.  Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.

[22]  Wilson Mok,et al.  Mathematical Modeling of Herpes Simplex Virus Distribution in Solid Tumors: Implications for Cancer Gene Therapy , 2009, Clinical Cancer Research.

[23]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[24]  T Lammers,et al.  Tumour-targeted nanomedicines: principles and practice , 2008, British Journal of Cancer.

[25]  V. Torchilin.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[26]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[27]  R. Jain,et al.  Non-Uniform Plasma Leakage Affects Local Hematocrit and Blood Flow: Implications for Inflammation and Tumor Perfusion , 2007, Annals of Biomedical Engineering.

[28]  T. Secomb,et al.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.

[29]  C. Pozrikidis,et al.  A Model of Fluid Flow in Solid Tumors , 2003, Annals of Biomedical Engineering.

[30]  S. Halford,et al.  A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Jain,et al.  Tumor pretargeting for radioimmunodetection and radioimmunotherapy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  R. Jain,et al.  Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. , 1996, Microvascular research.

[34]  R. Jain,et al.  Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. , 1996, British Journal of Cancer.

[35]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[36]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[37]  R. Jain,et al.  Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. , 1989, Cancer research.

[38]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.